Clinical trial
Safety and Tolerability of Low-Dose Temozolomide During Whole Brain Radiation in…
NCT00266812 · Merck Sharp & Dohme LLC, Industry · Terminated
Key facts
| NCT number | NCT00266812 |
|---|---|
| Title | Safety and Tolerability of Low-Dose Temozolomide During Whole Brain Radiation in Patients With Cerebral Metastases From Non-Small-Cell Lung Cancer (Study P04071)(TERMINATED) |
| Official title | Randomized Phase II Study: Temozolomide (TMZ) Concomitant to Radiotherapy Followed by Sequential TMZ in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Central Nervous System (CNS) Metastasis Versus Radiotherapy Alone |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Collaborators | AESCA Pharma GmbH Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small-Cell Lung |
| Intervention type | Drug, Procedure |
| Interventions | Temozolomide and radiotherapy, Whole brain radiotherapy |
| Enrollment | 35 |
| Start date | Mar 8, 2005 |
| Primary completion | Jan 16, 2008 |
| Completion | Jan 16, 2008 |
| First posted | Dec 19, 2005 |
| Last update posted | Jun 8, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: